Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the accessibility of beauty products for individuals with upper extremity disabilities. By examining various factors such as packaging design, product applicators, and ease of use, this research aims to identify barriers faced by individuals with upper extremity disabilities or visual deficits when using beauty products. The study seeks to provide insights and recommendations for improving the accessibility of beauty products, ultimately promoting inclusivity and enhancing the overall beauty experience for individuals with disabilities.

Clinical Trial Description

Individuals with upper extremity disabilities face unique challenges when it comes to using beauty products. These disabilities can include conditions such as limb loss, limited mobility, or dexterity impairments, which can significantly impact their ability to engage in self-care and beauty routines. The accessibility of beauty products is crucial to ensure that individuals with upper extremity disabilities have equal opportunities to participate in activities that promote self-expression and confidence. Research in the field of accessible design has highlighted the importance of inclusive product development across various industries, including cosmetics and personal care. However, limited attention has been given specifically to beauty products and their usability for individuals with upper extremity disabilities. To address this gap, studies are being conducted to assess the accessibility of beauty products and identify potential barriers and solutions. These studies typically examine factors such as packaging design, ergonomics of product applicators, ease of grip, and maneuverability. By understanding the specific challenges faced by individuals with upper extremity disabilities, researchers can propose modifications and design considerations that enhance accessibility. ;

Study Design

Related Conditions & MeSH terms

Amyotrophic Lateral Sclerosis
Brain Injuries
Brain Injuries, Traumatic
Ehlers-Danlos Syndrome
Graves Disease
Guillain-Barre Syndrome
Hemorrhagic Stroke
Ischemic Stroke
Lupus Erythematosus
Motor Neuron Disease
Multiple Sclerosis
Muscular Dystrophies
Myasthenia Gravis
SCI - Spinal Cord Injury
Sclerosis
Spinal Cord Injuries
Stroke
Stroke (CVA) or TIA
Stroke Hemorrhagic
Stroke, Acute
Stroke, Ischemic
Syndrome
Traumatic Brain Injury
Wounds and Injuries

Clinical Trial Details

NCT number	NCT05945784
Study type	Observational
Source	Casa Colina Hospital and Centers for Healthcare
Contact
Status	Completed
Phase
Start date	July 21, 2023
Completion date	September 29, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05528666` - Risk Perception in Multiple Sclerosis
Completed	`NCT03608527` - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis	N/A
Recruiting	`NCT05532943` - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis	Phase 1/Phase 2
Completed	`NCT02486640` - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed	`NCT01324232` - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis	Phase 2
Completed	`NCT04546698` - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting	`NCT04380220` - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed	`NCT02835677` - Integrating Caregiver Support Into MS Care	N/A
Completed	`NCT03686826` - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting	`NCT05964829` - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis	N/A
Withdrawn	`NCT06021561` - Orofacial Pain in Multiple Sclerosis
Completed	`NCT03653585` - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting	`NCT04798651` - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis	N/A
Active, not recruiting	`NCT05054140` - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis	Phase 2
Completed	`NCT05447143` - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis	N/A
Recruiting	`NCT06195644` - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients	Phase 1
Completed	`NCT04147052` - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis	N/A
Completed	`NCT03591809` - Combined Exercise Training in Patients With Multiple Sclerosis	N/A
Completed	`NCT03594357` - Cognitive Functions in Patients With Multiple Sclerosis
Completed	`NCT03269175` - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.